John Houston, Ph.D., has served as a member of our board of directors since September 2017. Dr. Houston has served as a consultant for us since February 2026. Dr. Houston served as our President and Chief Executive Officer from September 2017 to February 2026, and as Chair of our board of directors from June 2023 to February 2026. Dr. Houston served as our President of Research and Development from January 2017 to June 2024, as our Chief Scientific Officer from January 2017 to April 2019 and served as our principal executive officer from February 2017 to February 2026. Prior to joining Arvinas, Dr. Houston served in positions of increasing responsibility at Bristol-Myers Squibb Company, a biopharmaceutical company, or BMS, most recently as Senior Vice President, Head of Specialty Discovery from September 2015 to August 2016, and as Senior Vice President of Disease Sciences, Biologics and Applied Biotechnology from August 2008 to September 2015. Prior to joining BMS, Dr. Houston worked at Glaxo Wellcome Research and Development in the UK, where he served as head of the Lead Discovery Unit. Dr. Houston currently serves on the board of directors of the publicly-traded company, NextCure, Inc. Dr. Houston holds a Ph.D. in microbial biochemistry from Heriot-Watt University, Edinburgh and a B.Sc. in medical microbiology from the University of Glasgow. We believe Dr. Houston is qualified to serve on our board of directors due to his scientific and historical experience with us gained from serving as our former President and Chief Executive Officer, combined with his previous scientific training and qualifications and the skills and experience he has developed during his extensive career in the life sciences industry.